Carbenicillin
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Carbenicillin
- Pharmacist Assessment Report
- Carbenicillin: Extended-spectrum penicillin (beta-lactam) → Ureaplasma urethritis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Carbenicillin: Extended-spectrum penicillin (beta-lactam) → Ureaplasma urethritis
One-Sentence Summary
Carbenicillin is an extended-spectrum penicillin that blocks bacterial cell wall synthesis. The TxGNN model predicts it may be effective for Ureaplasma urethritis, with a score of 0.9998, but no clinical trials and no publications support this prediction. The mechanism is also doubtful, because Ureaplasma bacteria have no cell wall for a beta-lactam to attack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Ureaplasma urethritis |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Based on its drug class, carbenicillin is a beta-lactam that inhibits bacterial cell wall synthesis, and it has activity against many urinary-tract bacteria.
For Ureaplasma urethritis, however, this mechanism does not fit. Ureaplasma species lack a cell wall, so beta-lactams are expected to be intrinsically ineffective. The high TxGNN score most likely reflects the drug’s general association with urogenital infections rather than a real pharmacological link. The prediction should therefore be treated as a weak, unsupported signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 50906 | CARBELIN 5GM INJECTION | Vial of 1 injection | Not recorded |
| 42088 | CARBELIN 1GM INJECTION | Vial of 1 injection | Not recorded |
Both licences are valid single-ingredient products from Lyka Labs.
Safety Considerations
- Drug Interactions: 18 interactions were found. The most important is methotrexate (Major). Moderate interactions include warfarin, dicoumarol, tetracyclines (doxycycline, minocycline, tetracycline, demeclocycline, oxytetracycline), chloramphenicol, ethinylestradiol, mycophenolic acid, pemetrexed, balsalazide, picosulfuric acid and radioactive iodide (I-123, I-131). Clarithromycin and erythromycin are Minor.
For other safety information, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale:
- There is no clinical or published evidence for Ureaplasma urethritis, and the lack of a bacterial cell wall in Ureaplasma argues against any benefit from a beta-lactam. The prediction is supported by the model score alone.
To proceed, the following is needed:
- Laboratory data showing carbenicillin activity against Ureaplasma, which is unlikely given the mechanism
- Detailed mechanism-of-action data
- Package insert warnings and contraindications
- A comparison against current standard treatments for Ureaplasma infection, which use agents that do not depend on a cell wall
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.